Do we need to optimize plasma protein and tissue binding in drug discovery?

Current Topics in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 450-466

  Liu, Xingrong ^a   Chen, Cuiping ^b   Hop, Cornelis E C A ^a  

^a GENENTECH INC   (United States)

^b Pharmacokinetics Depomed Inc   (United States)

Author keywords

And tissue binding; Clearance; Drug design; Free unbound drug concentration; Plasma protein binding

Indexed keywords

DRUG BINDING PROTEIN; PLASMA PROTEIN;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; MAXIMUM PLASMA CONCENTRATION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BINDING SITES; BLOOD PROTEINS; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 79551662332     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611794480918     Document Type: Article

References (60)

1. Liu, X.; Chen, C. Strategies to optimize brain penetration in drug discovery. Curr. Opin. Drug Discov. Devel., 2005, 8, 505-512.
2. Trainor, G. The importance of plasma protein binding in drug discovery. Expert. Opin. Drug Discov., 2007, 2, 51-64.
3. Hammarlund-Udenaes, M.; Friden, M.; Syvanen, S.; Gupta, A. On the rate and extent of drug delivery to the brain. Pharm. Res., 2008, 25, 1737-1750.
4. Lin, J. H. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr. Drug Metab., 2008, 9, 46-59.
5. Schmidt, S.; Gonzalez, D.; Derendorf, H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2010, 99, 1107-1122.
6. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther., 2008, 325, 349-356.
7. Banker, M. J.; Clark, T. H.; Williams, J. A. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci., 2003, 92, 967-974.
8. Kariv, I.; Cao, H.; Oldenburg, K. R. Development of a high throughput equilibrium dialysis method. J. Pharm. Sci., 2001, 90, 580-587.
9. Fung, E. N.; Chen, Y. H.; Lau, Y. Y. Semi-automatic highthroughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci., 2003, 795, 187-194.
10. Wan, H.; Rehngren, M. High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry. J. Chromatogr. A, 2006, 1102, 125-134.
11. Waters, N. J.; Jones, R.; Williams, G.; Sohal, B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci., 2008, 97, 4586-4595.
12. Aureli, L.; Cruciani, G.; Cesta, M. C.; Anacardio, R.; De Simone, L.; Moriconi, A. Predicting human serum albumin affinity of interleukin- 8 (CXCL8) inhibitors by 3D-QSPR approach. J. Med. Chem., 2005, 48, 2469-2479.
13. Gleeson, M. P. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. J. Med. Chem., 2007, 50, 101-112.
14. Wang, J.; Krudy, G.; Xie, X. Q.; Wu, C.; Holland, G. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion. J. Chem. Inf. Model, 2006, 46, 2674-2683.
15. Yamazaki, K.; Kanaoka, M. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. J. Pharm. Sci., 2004, 93, 1480-1494.
16. Kratochwil, N. A.; Huber, W.; Muller, F.; Kansy, M.; Gerber, P. R. Predicting plasma protein binding of drugs: a new approach. Biochem. Pharmacol., 2002, 64, 1355-1374.
17. Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M. H.; Reynolds, D. P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm. Sci., 2003, 92, 2236-2248.
18. Brunton, L.; Lazo, J.; Parker, K. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; McGraw-Hill: New York, 2006.
19. Obach, R. S.; Lombardo, F.; Waters, N. J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos., 2008, 36, 1385-1405.
20. Bass, L.; Robinson, P.; Bracken, A. J. Hepatic elimination of flowing substrates: the distributed model. J. Theor. Biol., 1978, 72, 161-184.
21. Pang, K. S.; Rowland, M. Hepatic clearance of drugs. I. Theoretical considerations of a well-stirred model and a parallel tube model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm., 1977, 5, 625-653.
22. Pang, K. S.; Rowland, M. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the well-stirred model over the parallel tube model using lidocaine in the perfused rat liver in situ preparation. J. Pharmacokinet. Biopharm., 1977, 5, 655-680.
23. Pang, K. S.; Rowland, M. Hepatic clearance of drugs. III. Additional experimental evidence supporting the well-stirred model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. J. Pharmacokinet. Biopharm., 1977, 5, 681-699.
24. Roberts, M. S.; Rowland, M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm., 1986, 14, 227-260.
25. Roberts, M. S.; Rowland, M. A dispersion model of hepatic elimination: 2. Steady-state considerations--influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J. Pharmacokinet. Biopharm., 1986, 14, 261-288.
26. Roberts, M. S.; Rowland, M. A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. J. Pharmacokinet. Biopharm., 1986, 14, 289-308.
27. Forker, E. L.; Luxon, B. Hepatic transport kinetics and plasma disappearance curves: distributed modeling versus conventional approach. Am. J. Physiol., 1978, 235, E648-660.
28. Berezhkovskiy, L. M. On the influence of protein binding on pharmacological activity of drugs. J. Pharm. Sci., 2010, 99, 2153-2165.
29. Brouwer, K.L.R.; Thurman, R.G. In: Models for Assessing Drug Absorption and Metabolism; Borchardt; Smith; Wilson, ed.; Plenum Press: New York, 1996.
30. Jones, D. B.; Morgan, D. J.; Mihaly, G. W.; Webster, L. K.; Smallwood, R. A. Discrimination between the venous equilibrium and sinusoidal models of hepatic drug elimination in the isolated perfused rat liver by perturbation of propranolol protein binding. J. Pharmacol. Exp. Ther., 1984, 229, 522-526.
31. Smallwood, R. H.; Morgan, D. J.; Mihaly, G. W.; Jones, D. B.; Smallwood, R. A. Effect of plasma protein binding on elimination of taurocholate by isolated perfused rat liver: comparison of venous equilibrium, undistributed and distributed sinusoidal, and dispersion models. J. Pharmacokinet. Biopharm., 1988, 16, 377-396.
32. Diaz-Garcia, J. M.; Evans, A. M.; Rowland, M. Application of the axial dispersion model of hepatic drug elimination to the kinetics of diazepam in the isolated perfused rat liver. J. Pharmacokinet. Biopharm., 1992, 20, 171-193.
33. Nagase, S.; Shimamune, K.; Shumiya, S. Albumin-deficient ratmutant. Science, 1979, 205, 590-591.
34. Miida, H.; Arakawa, S.; Shibaya, Y.; Honda, K.; Kiyosawa, N.; Watanabe, K.; Manabe, S.; Takasaki, W.; Ueno, K. Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). J. Toxicol. Sci., 2008, 33, 349-361.
35. Benet, L. Z.; Hoener, B. A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther., 2002, 71, 115-121.
36. Toutain, P. L.; del Castillo, J. R.; Bousquet-Melou, A. The pharmacokinetic- pharmacodynamic approach to a rational dosage regimen for antibiotics. Res. Vet. Sci., 2002, 73, 105-114.
37. Blakey, G. E.; Nestorov, I. A.; Arundel, P. A.; Aarons, L. J.; Rowland, M. Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J. Pharmacokinet. Biopharm., 1997, 25, 277-312.
38. Kalvass, J. C.; Maurer, T. S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug. Dispos., 2002, 23, 327-338.
39. Boffito, M.; Back, D. J.; Blaschke, T. F.; Rowland, M.; Bertz, R. J.; Gerber, J. G.; Miller, V. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retrovirus., 2003, 19, 825-835.
40. Boxenbaum, H.; Battle, M. Effective half-life in clinical pharmacology. J. Clin. Pharmacol., 1995, 35, 763-766.
41. Oie, S.; Tozer, T. N. Effect of altered plasma protein binding on apparent volume of distribution. J. Pharm. Sci., 1979, 68, 1203-1205.
42. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther., 1997, 283, 46-58.
43. Gibaldi, M.; Perrier, D. Pharmacokinetics, 2nd ed.; Marcel Dekker: New York, 1982.
44. Lombardo, F.; Obach, R. S.; Shalaeva, M. Y.; Gao, F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J. Med. Chem., 2004, 47, 1242-1250.
45. Lombardo, F.; Obach, R. S.; Shalaeva, M. Y.; Gao, F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem., 2002, 45, 2867-2876.
46. Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J. Med. Chem., 2001, 44, 2490-2497.
47. Hammarlund-Udenaes, M.; Paalzow, L. K.; de Lange, E. C. Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method. Pharm. Res., 1997, 14, 128-134.
48. Maurer, T. S.; Debartolo, D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab. Dispos., 2005, 33, 175-181
49. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E.; Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of Pglycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug. Metab. Dispos., 2005, 33, 165-174.
50. Summerfield, S. G.; Read, K.; Begley, D. J.; Obradovic, T.; Hidalgo, I. J.; Coggon, S.; Lewis, A. V.; Porter, R. A.; Jeffrey, P. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther., 2007, 322, 205-213.
51. Summerfield, S. G.; Stevens, A. J.; Cutler, L.; del Carmen Osuna, M.; Hammond, B.; Tang, S. P.; Hersey, A.; Spalding, D. J.; Jeffrey, P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther., 2006, 316, 1282-1290.
52. Liu, X.; Vilenski, O.; Kwan, J.; Apparsundaram, S.; Weikert, R., Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab. Dispos. 2009, 37, 1548-1556.
53. Becker, S.; Liu, X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab. Dispos., 2006, 34, 855-861.
54. Liu, X., Van Natta, K.; Yeo, H.; Vilenski, O.; Weller, P. E.; Worboys, P. D.; Monshouwer, M. Unbound drug concentrations in brain homogenate and cerebral spinal fluid drug concentrations at steady state as a surrogate for unbound drug concentrations in brain interstitial fluid. Drug Metab. Dispos., 2008, 37, 787-793.
55. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab. Dispos., 2006, 34, 1443-1447.
56. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van, D. J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J. Pharmacol. Exp. Ther., 2005, 313, 1254-1262.
57. Kalvass, J. C.; Olson, E. R.; Cassidy, M. P.; Selley, D. E.; Pollack, G. M. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J. Pharmacol. Exp. Ther., 2007, 323, 346-355.
58. Watson, J.; Wright, S.; Lucas, A.; Clarke, K. L.; Viggers, J.; Cheetham, S.; Jeffrey, P.; Porter, R.; Read, K. D. Receptor occupancy and brain free fraction. Drug Metab. Dispos., 2009, 37, 753-760.
59. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships. J. Med. Chem., 2006, 49, 7559-7583.
60. Gupta, A.; Hammarlund-Udenaes, M.; Chatelain, P.; Massingham, R.; Jonsson, E. N. Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. Biopharm. Drug Dispos., 2006, 27, 291-297.